Irritable bowel syndrome: a spotlight on future research needs.

Published on Apr 16, 2021in The Lancet Gastroenterology & Hepatology14.789
· DOI :10.1016/S2468-1253(21)00131-X
Christopher J Black13
Estimated H-index: 13
(St James's University Hospital),
Alexander C. Ford86
Estimated H-index: 86
(St James's University Hospital)
Sources
Abstract
References10
Newest
#1Brigida Barberio (UNIPD: University of Padua)H-Index: 7
#2Lesley A. Houghton (University of Leeds)H-Index: 53
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Introduction Irritable bowel syndrome (IBS) is a chronic functional bowel disorder, which follows a relapsing and remitting course. Little is known about how evolving definitions of IBS or treatment for the condition affect symptom stability. We conducted a 12-month longitudinal follow-up study of individuals who self-identified as having IBS to examine these issues. Methods We collected demographic, gastrointestinal symptom, mood, and psychological health data at baseline, and gastrointestinal ...
4 CitationsSource
#1Christopher J Black (St James's University Hospital)H-Index: 13
#2Yan Yiannakou (County Durham and Darlington NHS Foundation Trust)H-Index: 13
Last. Alexander C. Ford (St James's University Hospital)H-Index: 86
view all 6 authors...
INTRODUCTION: Conventionally, patients with irritable bowel syndrome (IBS) are subgrouped based on their predominant bowel habit. Given the relevance of psychological comorbidity to IBS symptoms, our aim was to explore an alternative approach to subgrouping by incorporating factors beyond stool form and frequency. METHODS: We collected demographic, symptom, and psychological health data from 1,375 adult subjects in the community who self-identified as having IBS, identifying 2 cohorts meeting ei...
6 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 5 authors...
Gastrointestinal symptoms are highly prevalent, but many people who have them will have no organic explanation for their symptoms. Most of these people will be labelled as having a functional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or functional constipation. These conditions affect up to 40% of people at any one point in time, and two-thirds of these people will have chronic, fluctuating symptoms. The pathophysiology of functional gastrointestinal diso...
11 CitationsSource
#1Priya Oka (University of Leeds)H-Index: 1
#2Heather Parr (University of Leeds)H-Index: 1
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Summary Background Irritable bowel syndrome (IBS) is one of the most common functional bowel disorders, but community prevalence appears to vary widely between different countries. This variation might be due to the fact that previous cross-sectional surveys have neither applied uniform diagnostic criteria nor used identical methodology, rather than being due to true global variability. We aimed to determine the global prevalence of IBS. Methods We did a systematic review and meta-analysis of da...
24 CitationsSource
#1Christopher J BlackH-Index: 13
#2Elyse R. ThakurH-Index: 1
Last. Alexander C. FordH-Index: 86
view all 6 authors...
Objectives National guidelines for the management of irritable bowel syndrome (IBS) recommend that psychological therapies should be considered, but their relative efficacy is unknown, because there have been few head-to-head trials. We performed a systematic review and network meta-analysis to try to resolve this uncertainty. Design We searched the medical literature through January 2020 for randomised controlled trials (RCTs) assessing efficacy of psychological therapies for adults with IBS, c...
24 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 8 authors...
Objective Over half of patients with IBS have either diarrhoea (IBS-D) or a mixed stool pattern (IBS-M). The relative efficacy of licenced pharmacological therapies is unclear in the absence of head-to-head trials. We conducted a network meta-analysis to resolve this uncertainty. Design We searched MEDLINE, Embase, Embase Classic, the Cochrane central register of controlled trials, and Clinicaltrials.gov through January 2019 to identify randomised controlled trials (RCTs) assessing the efficacy ...
31 CitationsSource
#1Hazel Everitt (University of Southampton)H-Index: 22
#2Sabine Landau (University of Cambridge)H-Index: 70
Last. Rona Moss-Morris (University of Cambridge)H-Index: 70
view all 15 authors...
Objective To evaluate the clinical effectiveness of two modes of cognitive–behavioural therapy (CBT) for IBS compared with treatment as usual (TAU) in refractory IBS. Design A three-arm randomised controlled trial assessing telephone-delivered CBT (TCBT), web-based CBT (WCBT) with minimal therapist support, and TAU. Blinding participants and therapists was not possible. Chief investigator, assessors and statisticians were blinded. Participants were adults with refractory IBS (clinically signific...
72 CitationsSource
Summary Background Hypnotherapy for irritable bowel syndrome (IBS) has been used primarily in patients with refractory symptoms in specialised departments and delivered on an individual basis. We aimed to test the hypothesis that hypnotherapy would be more effective than educational supportive therapy, and that group hypnotherapy would be non-inferior to individual hypnotherapy for patients with IBS referred from primary and secondary care. Methods We did a multicentre randomised controlled tria...
27 CitationsSource
#1Christopher J Black (University of Leeds)H-Index: 13
#2Nicholas E Burr (University of Leeds)H-Index: 14
Last. Alexander C. Ford (University of Leeds)H-Index: 86
view all 6 authors...
Background & Aims Several secretagogues have been approved for the treatment of irritable bowel syndrome with constipation (IBS-C). However, their relative efficacy is unclear because there have been no head-to-head randomized controlled trials. We conducted a network meta-analysis to compare their efficacies in patients with IBS-C. Methods We searched MEDLINE, EMBASE, EMBASE Classic, and the Cochrane Central Register of Controlled Trials through June 2018 to identify randomized controlled trial...
52 CitationsSource
#1Douglas A. Drossman (UNC: University of North Carolina at Chapel Hill)H-Index: 103
#2Jan Tack (Katholieke Universiteit Leuven)H-Index: 126
Last. Lukas Van Oudenhove (Katholieke Universiteit Leuven)H-Index: 39
view all 6 authors...
Background & Aims Central neuromodulators (antidepressants, antipsychotics, and other central nervous system−targeted medications) are increasingly used for treatment of functional gastrointestinal disorders (FGIDs), now recognized as disorders of gut−brain interaction. However, the available evidence and guidance for the use of central neuromodulators in these conditions is scanty and incomplete. In this Rome Foundation Working Team report, a multidisciplinary team summarized available research...
96 CitationsSource
Cited By0
Newest